An Unparalleled Investment Opportunity

An Unparalleled Investment Opportunity: CAVADEX® and the Billion-Dollar Inflection Point.
Cardiovascular Disease (CVD) is the world’s #1 killer, affecting over 620 million people globally. For decades, the medical industry’s best defense—statins—has only managed symptoms and slowed progression.
Cholrem Pty Ltd has shattered the status quo.

We introduce CAVADEX®, a groundbreaking, scientifically validated therapy that doesn't just treat heart disease—it reverses it.
Validated by a landmark peer-reviewed study published in Cardiology Research and Cardiovascular Medicine (August 2025), CAVADEX® actively dissolves arterial plaque and dangerous cholesterol crystals at the source.

"It's the greatest advance that we have had in cardiovascular pharmacology... since the statins came on the scene." — Professor Laurie Howes, MB BS PhD FRACP FCSANZ (40+ years in Cardiovascular Pharmacology)

A De-Risked Pathway to a Trillion-Dollar Market
This is not a typical early-stage biotech investment. Cholrem is not navigating years of R&D uncertainty. We are a revenue-generating company with a proven product, positioned for exponential growth.
• Proven Human Efficacy: Real-world data and pilot studies demonstrate a remarkable 92% success rate in plaque regression.
• Established Revenue: CAVADEX® has been in production and selling worldwide for over five years.
• Safety Assured: The active ingredient is already FDA-approved (GRAS) with a long-established, non-toxic safety profile.
• Immediate Scalability: Robust, proven manufacturing infrastructure capable of immediately scaling to $25 Million USD in weekly revenue from a single site.

The Catalyst: Formal Clinical Trials
We are at a critical inflection point. We are seeking strategic capital to initiate accelerated clinical trials. The final step to validate our extensive real-world evidence and unlock global market dominance.

These aren’t just any trials, we are going for the Holy Grail of trials. Calcium scores are the leading indicator of heart disease and, until now, have been considered irreversible. No existing therapy can reduce them. We will show calcium scores plummeting within 3 months. We know this because we are seeing it every day from customers using Cavadex.
The commencement of these 3 month trials, scheduled for early November 2025, will serve as a massive commercial catalyst.
Given the proven efficacy and the scale of the addressable market (capturing just 10% of the U.S. market projects revenues exceeding $3.15 billion USD per MONTH!), we project this milestone will elevate Cholrem to a billion-dollar valuation.

The Opportunity
We are offering equity in Cholrem Pty Ltd for this pivotal, limited funding round.
$100,000 per 1% share. Limited round up to $2 million (20% equity) to fund trials and ignite global dominance.
This is a rare opportunity to generate exceptional returns while funding the most significant revolution in cardiovascular health in a generation.

Own a substantial equity share in a potentially multibillion-dollar company.
Request the Business Brief and scientific documentation today.
Visit: www.cholrem.com
Contact: Kyle Hodgetts,
Founder & CEO